Indraprastha Medical Corporation Ltd

Indraprastha Medical Corporation announced that Dr. Menaka Guruswamy (DIN 08742679) has completed her tenure viz. first term of five (5) consecutive years on 22 May 2025, as Independent Director on the Board of Directors of the Company. Owing to her professional commitments & law practice as a Senior Advocate at the Supreme Court of India, she has opted not to renew her second term as an Independent Director on the Board of Directors of the Company. Consequently, she cease to be the Independent Director of the CompanyPowered by Capital Market - Live

Indraprastha Medical Corporation announced that the Board of Directors of the Company at its meeting held on 16 May 2025, inter alia, have recommended the final dividend of Rs 4.5 per equity Share (i.e. 45%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Indraprastha Medical Corporation rose 31.57% to Rs 41.01 crore in the quarter ended March 2025 as against Rs 31.17 crore during the previous quarter ended March 2024. Sales rose 6.04% to Rs 333.75 crore in the quarter ended March 2025 as against Rs 314.73 crore during the previous quarter ended March 2024. For the full year,net profit rose 29.87% to Rs 160.99 crore in the year ended March 2025 as against Rs 123.96 crore during the previous year ended March 2024. Sales rose 8.97% to Rs 1356.36 crore in the year ended March 2025 as against Rs 1244.70 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales333.75314.73 6 1356.361244.70 9 OPM %18.3715.39 -18.0115.53 - PBDT66.1851.77 28 260.65206.19 26 PBT55.2741.56 33 216.32166.11 30 NP41.0131.17 32 160.99123.96 30 Powered by Capital Market - Live

Indraprastha Medical Corporation will hold a meeting of the Board of Directors of the Company on 16 May 2025.Powered by Capital Market - Live

The agency has also affirmed the company's short term rating at '[ICRA] A1+'. ICRA stated that the rating action factors in Indraprastha Medical Corporation Limited (IMCL)'s established presence and strong market position in the NCR region, its healthy operating metrics and its robust financial profile. The ratings also factor in IMCL's revenue diversification across specialities, including oncology, neurology, cardiology and nephrology, among others. The financial risk profile remains comfortable as reflected by minimal gearing, robust debt protection indicators and a strong liquidity profile. Further, the ratings factor in the strong parentage of Apollo Hospitals Enterprise Limited (AHEL) along with its promoters, holding a 25% stake in IMCL. The entity has significant operational, financial and managerial linkages with AHEL. Apollo Hospitals is among the leading healthcare players, operating one of the largest hospital chains in the country. However, the ratings remain constrained by the geographical and asset concentration risks, as IMCL's operations are concentrated across two hospitals in the National Capital Region (NCR). Like other entities in the sector, IMCL remains exposed to regulatory risks, with previous restrictions imposed by various authorities. The ratings also factor in the competitive pressures and the necessity to retain medical talent in an ever-evolving market. Incorporated in 1988 as a JV between Apollo Hospitals Enterprise (AHEL) and the Delhi Government, Indraprastha Medical Corporation (IMCL) is a 749-bedded, super speciality tertiary care hospital in New Delhi and Noida. The scrip gained 3.09% to currently trade at Rs 415.30 on the BSE. Powered by Capital Market - Live

Indraprastha Medical Corporation will hold a meeting of the Board of Directors of the Company on 3 February 2025.Powered by Capital Market - Live

Net profit of Indraprastha Medical Corporation rose 29.07% to Rs 42.40 crore in the quarter ended September 2024 as against Rs 32.85 crore during the previous quarter ended September 2023. Sales rose 10.35% to Rs 349.82 crore in the quarter ended September 2024 as against Rs 317.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales349.82317.00 10 OPM %18.1915.89 - PBDT68.1053.68 27 PBT56.9343.65 30 NP42.4032.85 29 Powered by Capital Market - Live

Indraprastha Medical Corporation will hold a meeting of the Board of Directors of the Company on 30 October 2024.Powered by Capital Market - Live

Indraprastha Medical Corporation announced that the 36th Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live

Net profit of Indraprastha Medical Corporation rose 46.79% to Rs 44.77 crore in the quarter ended June 2024 as against Rs 30.50 crore during the previous quarter ended June 2023. Sales rose 13.49% to Rs 347.86 crore in the quarter ended June 2024 as against Rs 306.51 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales347.86306.51 13 OPM %19.3015.42 - PBDT70.6350.04 41 PBT59.5940.23 48 NP44.7730.50 47 Powered by Capital Market - Live